These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6198637)

  • 1. [Induction of remission in patients with non-Hodgkin lymphomas with high degree of malignancy - preliminary comparison of 2 chemotherapy programs: CHOP-B (cyclophosphamide, adriamycin, vincristine, encorton, bleomycin) and MEV-A (methotrexate, cyclophosphamide, vincristine and adriamycin)].
    Walewski JA
    Nowotwory; 1983; 33(3):259-65. PubMed ID: 6198637
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols].
    Płuzańska A; Krykowski E; Robak T; Oliskiewicz W; Polkowska E; Dowgier I; Hyjek E
    Pol Tyg Lek; 1982 Sep; 37(36):1049-53. PubMed ID: 6189105
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial.
    Hagberg H; Björkholm M; Glimelius B; Lindemalm C; Mellstedt H; Killander A
    Eur J Cancer Clin Oncol; 1985 Feb; 21(2):175-9. PubMed ID: 3886392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of treatment of the lymphoblastic and immunoblastic malignant lymphomas using the CHOP-bleo protocol (cyclophosphamide, doxorubicin, vincristine, bleomycin and prednisolone)].
    Płuzańska A; Kowalczyński M; Polkowska E; Stempczyńska J; Hyjek E
    Pol Arch Med Wewn; 1982; 68(1-2):55-64. PubMed ID: 6186997
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for large-cell lymphoma: optimism and caution.
    Coleman M
    Ann Intern Med; 1985 Jul; 103(1):140-2. PubMed ID: 2408529
    [No Abstract]   [Full Text] [Related]  

  • 10. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].
    Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC
    Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.
    Ginsberg SJ; Anderson JR; Gottlieb AJ; Bloomfield CD; Norton L; Barcos M; Holland JF
    NCI Monogr; 1987; (5):77-80. PubMed ID: 2448657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
    J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic malignancies: non-Hodgkin's lymphomas.
    DeVita VT
    Hosp Pract (Off Ed); 1986 Sep; 21(9):103-18. PubMed ID: 2427535
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
    Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
    Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preinduction in the treatment of patients with malignant lymphoma].
    Avilés A; García EL; Talavera A; Guzmán R; Diáz-Maqueo JC
    Gac Med Mex; 1991; 127(2):119-23. PubMed ID: 1720407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of malignant lymphoma in Jichi Medical School Hospital. 3) Treatment of advanced bad-risk lymphoma with the M-CHOP regimen].
    Furukawa Y; Takagi S; Tsuboyama A; Tsunoda S; Komatsu N; Takeda K; Muroi K; Ohsaka A; Miwa A; Yoshida M
    Rinsho Ketsueki; 1988 Jun; 29(6):833-9. PubMed ID: 3418885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.